[go: up one dir, main page]

AR051032A1 - ZIPRASIDONA PURIFICATION PROCESS - Google Patents

ZIPRASIDONA PURIFICATION PROCESS

Info

Publication number
AR051032A1
AR051032A1 ARP050103964A ARP050103964A AR051032A1 AR 051032 A1 AR051032 A1 AR 051032A1 AR P050103964 A ARP050103964 A AR P050103964A AR P050103964 A ARP050103964 A AR P050103964A AR 051032 A1 AR051032 A1 AR 051032A1
Authority
AR
Argentina
Prior art keywords
ziprasidona
purification process
formula
compound
acid
Prior art date
Application number
ARP050103964A
Other languages
Spanish (es)
Original Assignee
Medichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichem Sa filed Critical Medichem Sa
Publication of AR051032A1 publication Critical patent/AR051032A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un proceso para la purificación de 5-[2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]etil]-6-cloro-1,3-dihidro-2H-indol-2-ona de fórmula (1) a partir de una composición que comprende dicho compuesto, en el que dicho compuesto se hace reaccionar con ácido maleico o ácido acético para obtener la sal de adición de un ácido de la fórmula (2) en la que R es ~CH₃ o un resto de fórmula (3).Claim 1: A process for the purification of 5- [2- [4- (1,2-benzisothiazol-3-yl) -1-piperazinyl] ethyl] -6-chloro-1,3-dihydro-2H-indole- 2-one of formula (1) from a composition comprising said compound, wherein said compound is reacted with maleic acid or acetic acid to obtain the addition salt of an acid of the formula (2) in which R is ~ CH₃ or a remainder of formula (3).

ARP050103964A 2004-09-29 2005-09-21 ZIPRASIDONA PURIFICATION PROCESS AR051032A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200402316A ES2250001B1 (en) 2004-09-29 2004-09-29 PROCESS FOR THE PURIFICATION OF ZIPRASIDONA.

Publications (1)

Publication Number Publication Date
AR051032A1 true AR051032A1 (en) 2006-12-13

Family

ID=35431425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103964A AR051032A1 (en) 2004-09-29 2005-09-21 ZIPRASIDONA PURIFICATION PROCESS

Country Status (3)

Country Link
AR (1) AR051032A1 (en)
ES (1) ES2250001B1 (en)
WO (1) WO2006034965A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050346A1 (en) * 2005-03-07 2006-09-08 Dipharma Spa SOLID FORM OF CHLORIDATED ZIPRASIDONE
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
WO2011080749A1 (en) * 2009-12-29 2011-07-07 Hetero Research Foundation Process for purification of ziprasidone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
NZ508303A (en) * 1996-05-07 2001-07-27 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist
DE60124791T2 (en) * 2000-06-02 2007-09-13 Pfizer Products Inc., Groton S-methyl-dihydro-ziprasidone for the treatment of psychiatric disorders.
DE10043659A1 (en) * 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
UY27668A1 (en) * 2002-02-20 2003-10-31 Pfizer Prod Inc ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
AU2003260942A1 (en) * 2002-05-24 2003-12-12 Sun Pharmaceutical Industries Limited A process for the preparation of oxindole derivatives
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
WO2005035531A1 (en) * 2003-06-03 2005-04-21 Teva Paharmaceutical Industries Ltd. POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION

Also Published As

Publication number Publication date
ES2250001A1 (en) 2006-04-01
ES2250001B1 (en) 2007-06-01
WO2006034965A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
PE20050948A1 (en) CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
CY1110800T1 (en) ABIRATRONONE-3-STAR Methanesulfonic Salts and Recovery of ABIRATRONONE-3-STAR SALTS FROM SOLUTION TO THIR-BUTYLITHER
DK1041068T3 (en) Compounds for treating and preventing diabetic complications
UY30387A1 (en) NEW COMPOUNDS
PE20071326A1 (en) VIRAL POLYMERASE INHIBITORS
PE20050018A1 (en) HETEROAROMATIC PENTACYCLIC COMPOUND AS INHIBITOR OF PROTEIN TYROSINE PHOSPHATASE 1B (PTB1B)
EA201100996A1 (en) FUNCTIONAL COMPOSITION
SI2091948T1 (en) Novel inhibitors of glutaminyl cyclase
ATE396190T1 (en) SUBSTITUTED HETEROARYLALKANEOUS ACID AND THEREOF USE AS INHIBITORS OF ALDOSE REDUCTASE
TW200745069A (en) Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use
NO20072930L (en) Tripentyl citrates and their use
BR0207983A (en) Metalloproteinase Inhibitors
MA29431B1 (en) PYRAZOLE CARBOXYLIC ACID ANILIDES, PROCESSES FOR THEIR PRODUCTION AND AGENTS CONTAINING SAME FOR ANTIFUNGAL CONTROL
ATE427926T1 (en) CYCLOALKYLAMIN DERIVATIVES
ATE540928T1 (en) ISOQUINOLINE COMPOUNDS AND THEIR MEDICAL USES
EP2266961A3 (en) Process for the synthesis of organic compounds
EA200970372A1 (en) ALGHEIMER'S DISEASE INHIBITOR CONTAINING HETEROCYCLIC COMPOUND
PE20080364A1 (en) SUBSTITUTED BIPHENYLCARBOXYL ACID AND ITS DERIVATIVES AS MODULATORS OF THE ACTIVITY OF THE GAMMA-SECRETASE
PE20011115A1 (en) TRI-ARIL-SUBSTITUTED ETHANS, PDE4 INHIBITORS
NO20045497D0 (en) Process for Preparation of 5- (1,3-Oxazol-2-Yl) Benzoic Acid Derivatives
UY28897A1 (en) ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE
EA200600330A1 (en) SUBSTITUTED IMIDAZOPIRIMIDINES FOR PREVENTION AND TREATMENT OF CANCER
AR051032A1 (en) ZIPRASIDONA PURIFICATION PROCESS
BRPI0608400B8 (en) compound 2-(((4-((2,2-dimethyl-1,3-dioxan-5-yl)methoxy)-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzimidazole or a salt alkali metal of the same
JP2009513766A5 (en)

Legal Events

Date Code Title Description
FB Suspension of granting procedure